NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free MGX Stock Alerts $7.53 +0.79 (+11.72%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$6.66▼$7.6950-Day Range$6.68▼$12.2052-Week Range$6.50▼$12.74Volume139,371 shsAverage Volume109,835 shsMarket Capitalization$282.15 millionP/E RatioN/ADividend YieldN/APrice Target$21.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Metagenomi alerts: Email Address Metagenomi MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside184.2% Upside$21.40 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$13.03 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.89) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector369th out of 913 stocksBiological Products, Except Diagnostic Industry51st out of 152 stocks 4.5 Analyst's Opinion Consensus RatingMetagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMetagenomi has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MGX. Previous Next 0.0 Dividend Strength Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MGX. Previous Next 2.2 News and Social Media Coverage News SentimentMetagenomi has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Metagenomi this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,025,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Metagenomi are expected to grow in the coming year, from ($2.89) to ($2.68) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Metagenomi Stock (NASDAQ:MGX)Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Read More MGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Buy" by AnalystsApril 8, 2024 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 3, 2024 | fool.comMetagenomi (NASDAQ: MGX)April 2, 2024 | morningstar.comMetagenomi Inc MGXMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Robust Hemophilia Program and Strategic PartnershipsMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Promising Pipeline and Solid Financial PositioningMarch 28, 2024 | finanznachrichten.deMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2023 Financial ResultsApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 27, 2024 | msn.comMetagenomi reports FY resultsMarch 27, 2024 | globenewswire.comMetagenomi Reports Business Updates and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comMetagenomi to Participate in the 44th Annual Cowen Healthcare ConferenceFebruary 19, 2024 | fool.comThis Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It YetFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 13, 2024 | globenewswire.comMetagenomi Announces Closing of Initial Public OfferingFebruary 9, 2024 | reuters.comModerna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debutSee More Headlines Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)6/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CUSIPN/A CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Stock Price Target$21.40 High Stock Price Target$25.00 Low Stock Price Target$16.00 Potential Upside/Downside+184.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$44.76 million Price / Sales6.30 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares37,472,000Free FloatN/AMarket Cap$282.16 million OptionableN/A BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Brian Charles Thomas Ph.D. (Age 55)Co-Founder, CEO & Chairman of the Board Comp: $859.34kDr. Jian Irish M.B.A. (Age 60)Ph.D., President, COO & Director Comp: $729.82kDr. Sarah B. Noonberg M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $591.49kDr. Jak Knowles M.D.Co-Founder & Member of Scientific Advisory BoardMs. Pamela M. Wapnick M.B.A. (Age 58)Chief Financial Officer Dr. Luis G. Borges Ph.D. (Age 62)Chief Scientific Officer More ExecutivesKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCInvivydNASDAQ:IVVDBlack Diamond TherapeuticsNASDAQ:BDTXMonte Rosa TherapeuticsNASDAQ:GLUEAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInsidersHoldings A/S NovoBought 800,000 shares on 2/13/2024Total: $12 M ($15.00/share)Holdings A/S NovoBought 100,000 shares on 2/9/2024Total: $1.03 M ($10.25/share)View All Insider Transactions MGX Stock Analysis - Frequently Asked Questions Should I buy or sell Metagenomi stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Metagenomi in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGX shares. View MGX analyst ratings or view top-rated stocks. What is Metagenomi's stock price target for 2024? 6 Wall Street research analysts have issued 1 year price objectives for Metagenomi's stock. Their MGX share price targets range from $16.00 to $25.00. On average, they predict the company's share price to reach $21.40 in the next year. This suggests a possible upside of 184.2% from the stock's current price. View analysts price targets for MGX or view top-rated stocks among Wall Street analysts. How have MGX shares performed in 2024? Metagenomi's stock was trading at $10.31 at the beginning of 2024. Since then, MGX stock has decreased by 27.0% and is now trading at $7.53. View the best growth stocks for 2024 here. When is Metagenomi's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our MGX earnings forecast. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share. When did the company's quiet period expire? Metagenomi's quiet period expired on Wednesday, March 20th. Metagenomi had issued 6,250,000 shares in its public offering on February 9th. The total size of the offering was $93,750,000 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
